Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 15 Recruiting 8 Withdrawn 1 Completed 1

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 1

Interventions

Paclitaxel 489 Carboplatin 435 Gemcitabine 394 Docetaxel 385 Cisplatin 359 pembrolizumab 343 Bevacizumab 335 Nivolumab 261 Pemetrexed 242 Capecitabine 221 Dexamethasone 213 Fluorouracil 211 Rituximab 203 Trastuzumab 193 Cyclophosphamide 190 Oxaliplatin 160 Erlotinib Hydrochloride 147 Ipilimumab 145 atezolizumab 144 Prednisone 144 Cetuximab 142 Irinotecan 139 Leucovorin 130 Doxorubicin 130 Sorafenib 120 Lenalidomide 119 Bortezomib 118 Sunitinib 107 Everolimus 93 130-nm albumin-bound paclitaxel 91

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × INDUSTRY × belzutifan × Clear all

NCT04846920 2026-05-22

MK-6482-018

Merck Sharp & Dohme LLC

Phase 1 Completed

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡